The Asia-Pacific Journal of Ophthalmology

Asia-Pacific Journal of Ophthalmology:

Issue 4, July/August 2018 Review Article

Treatment of Ocular Myasthenia Gravis

Cornblath, Wayne T.



Author Information


From the Departments of Ophthalmology & Visual Sciences and Neurology, W.K. Kellogg Eye Center, University of Michigan, MI.


Reprints: Wayne T. Cornblath, MD, Departments of Ophthalmology & Visual Sciences and Neurology, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105. E-mail: wtc@med.umich.edu.



Abstract


Myasthenia gravis is a relatively common neuromuscular disorder, with ocular myasthenia gravis being a subset defined as myasthenia gravis limited to the orbicularis, levator, and extraocular muscles. Patients with ocular myasthenia gravis can have disabling diplopia or functional blindness from ptosis and in most cases treatment is required. Like generalized myasthenia gravis, there are a variety of treatments available that include pyridostigmine, immunosuppression, intravenous immunoglobulin, plasmapheresis, thymectomy, lid crutches, ptosis surgery, and extraocular muscle surgery. Unfortunately, there is limited data on the use of individual treatments in ocular myasthenia gravis and no data comparing treatments. Using a combination of available data on treatment of generalized myasthenia gravis, data on treatment of ocular myasthenia gravis, best practices, and clinical experience we will provide a rational framework for treatment of ocular myasthenia gravis.




Full Text

View PDF Online

Download PDF

APJO Express
2019
2018
2017
E-Newsletter+
2019
2018
2017
2016

More About APAO

  • http://www.apaophth.org/
  • http://2019.apaophth.org/
  • http://www.apaophth.org/apao-ldp/
  • http://www.apaophth.org/fellowship-program/
  • 1
  • 2
  • 3
  • 4
< >
All Rights Reserved © Asia-Pacific Academy of Ophthalmology  
Title×
Confirm
Cancel